{"id":92094,"date":"2026-07-20T09:07:26","date_gmt":"2026-07-20T09:07:26","guid":{"rendered":"https:\/\/www.europesays.com\/korea\/92094\/"},"modified":"2026-07-20T09:07:26","modified_gmt":"2026-07-20T09:07:26","slug":"samsung-biologics-offers-1-8-billion-for-polypeptide-a-significant-move-in-biotech-industry-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/korea\/92094\/","title":{"rendered":"Samsung Biologics Offers $1.8 Billion for PolyPeptide: A Significant Move in Biotech Industry, ETPharma"},"content":{"rendered":"<p>                        Bengaluru: South Korea&#8217;s <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/samsung+biologics\" class=\"news-keywords\" rel=\"nofollow noopener\" target=\"_blank\">Samsung Biologics<\/a> will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash bid for Swiss <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/contract+drugmaker\" class=\"news-keywords\" rel=\"nofollow noopener\" target=\"_blank\">contract drugmaker<\/a> <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/polypeptide\" class=\"news-keywords\" rel=\"nofollow noopener\" target=\"_blank\">PolyPeptide<\/a> , the companies said in separate statements.<\/p>\n<p>The offer at 44.31 Swiss francs per \u200cshare represents \u2060a premium \u2060of about 6.1% to PolyPeptide&#8217;s last closing price of 41.75 \u200bSwiss francs on Friday, according to a Reuters calculation.<\/p>\n<p>The tender offer \u200bis expected to launch by the end of August and close by year-end, Samsung Biologics said.<\/p>\n<p>The takeover \u200bwould expand the South Korean \u2060firm&#8217;s capabilities in \u200cpeptide-based therapeutics, including fast-growing obesity and diabetes \u200btreatments \u200bsuch as GLP-1 drugs, the company said.<\/p>\n<p>PolyPeptide said \u2060its board had unanimously recommended shareholders accept the \u200boffer.<\/p>\n<p>Samsung Biologics said after the deal \u200bwas completed it aimed to pursue a squeeze-out of any remaining minority shares and would delist PolyPeptide from the SIX Swiss Exchange, making it a wholly owned unit of the company.<\/p>\n<p>PolyPeptide said its \u200clargest individual shareholder, Draupnir Holding, which owns about 55.65% of the company, supported the deal and \u200bwould tender \u200ball of \u2060its shares into the offer.<\/p>\n<p>The Swiss company said in April that Draupnir was conducting a review of strategic options \u200bwith regard to its majority stake in PolyPeptide.<\/p>\n<p>Draupnir&#8217;s parent entity is the Cryosphere Foundation, which has links to Swedish billionaire Frederik Paulsen, PolyPeptide has said previously.<\/p>\n<p>(Reporting by Mihika Sharma in Bengaluru; Editing by Christian Schmollinger and Jamie Freed)\n            <\/p>\n<p>                    Published On Jul 20, 2026 at 07:23 AM IST<\/p>\n<p>        Most Read in Pharma Industry<\/p>\n<p>                    Join the community of 2M+ industry professionals.<br \/>\n                        Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.<\/p>\n<p>                Get updates on your preferred social platform<br \/>\n                Follow us for the latest news, insider access to events and more.<\/p>\n","protected":false},"excerpt":{"rendered":"Bengaluru: South Korea&#8217;s Samsung Biologics will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash bid for Swiss&hellip;\n","protected":false},"author":2,"featured_media":92095,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[48391,48393,48392,48217,127,505],"class_list":["post-92094","post","type-post","status-publish","format-standard","has-post-thumbnail","category-samsung-biologics","tag-1-8-billion-bid","tag-contract-drugmaker","tag-peptide-based-therapeutics","tag-polypeptide","tag-samsung","tag-samsung-biologics"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/92094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/comments?post=92094"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/92094\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media\/92095"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media?parent=92094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/categories?post=92094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/tags?post=92094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}